• Publications
  • Influence
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.
CD20 is a nonglycosylated 33 to 37 kD phosphoprotein involved in B-cell signaling that subserves important functions in the regulation of B-cell proliferation and differentiation. In addition, thisExpand
  • 608
  • 18
  • PDF
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Abstract Anti-CD20 monoclonal antibodies have been successfully employed in the clinical treatment of non-Hodgkin's lymphomas in both unmodified and radiolabeled forms. Previous publications haveExpand
  • 392
  • 16
Constitutive endocytosis and degradation of CD22 by human B cells.
The CD22 B lymphocyte-surface Ag is an important component of the B cell-surface IgM (sIgM)/B cell receptor complex and has been shown to regulate B cell activation. In addition, this molecule hasExpand
  • 108
  • 8
Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.
Radiolabeled antibodies have produced encouraging remissions in patients with chemotherapy-resistant hematological malignancies; however, the selection of therapeutic radionuclides for clinicalExpand
  • 210
  • 2
  • PDF
Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths.
The heavy (VH) and light (VL) chain variable regions of the murine anti-human CD20 mAb 1F5 were cloned, and four single-chain Ab (scFv) molecules were constructed using linker peptides of variableExpand
  • 56
  • 1
Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3ζ recombinant gene
One of the approaches to make anti-CD20 antibody more efficient is to express this antibody on the surface of T cells. scFv from anti-CD20 antibody has been expressed on T cell surface to bind toExpand
  • 19
  • 1
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Anti-CD20 monoclonal antibodies have been successfully employed in the clinical treatment of non-Hodgkin's lymphomas in both unmodified and radiolabeled forms. Previous publications have demonstratedExpand
  • 13
  • 1
Adoptive Antitumor Immunotherapy In Vitro and In Vivo Using Genetically Activated erbB2-specific T Cells
The use of human T lymphocytes genetically modified to express chimeric antigen receptors on their surfaces has emerged as a promising treatment strategy for malignant tumors. We have transfectedExpand
  • 10
  • 1
Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells.
Retinoids have been shown to be clinically useful in the biological therapy of certain myeloid and T-cell malignancies, whereas CD20 has proven to be an effective target in B-cell lymphomaExpand
  • 28
  • PDF